Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Nanobiotechnology. 2024 Oct 4;22(1):601. doi: 10.1186/s12951-024-02882-x.
Glioblastomas (GBMs) are the most common and aggressive malignant brain tumors, presenting significant challenges for treatment due to their invasive nature and localization in critical brain regions. Standard treatment includes surgical resection followed by radiation and adjuvant chemotherapy with temozolomide (TMZ). Recent advances in immunotherapy, including the use of mRNA vaccines, offer promising alternatives. This review focuses on the emerging use of mRNA vaccines for GBM treatment. We summarize recent advancements, evaluate current obstacles, and discuss notable successes in this field. Our analysis highlights that while mRNA vaccines have shown potential, their use in GBM treatment is still experimental. Ongoing research and clinical trials are essential to fully understand their therapeutic potential. Future developments in mRNA vaccine technology and insights into GBM-specific immune responses may lead to more targeted and effective treatments. Despite the promise, further research is crucial to validate and optimize the effectiveness of mRNA vaccines in combating GBM.
胶质母细胞瘤（GBM）是最常见和侵袭性最强的恶性脑肿瘤，由于其侵袭性和在关键脑区的定位，治疗存在重大挑战。标准治疗包括手术切除，然后进行放疗和替莫唑胺（TMZ）辅助化疗。免疫疗法的最新进展，包括使用 mRNA 疫苗，提供了有前途的替代方案。本综述重点介绍了用于 GBM 治疗的 mRNA 疫苗的新应用。我们总结了最近的进展，评估了当前的障碍，并讨论了该领域的显著成功。我们的分析表明，虽然 mRNA 疫苗显示出了潜力，但它们在 GBM 治疗中的应用仍处于实验阶段。正在进行的研究和临床试验对于充分了解其治疗潜力至关重要。mRNA 疫苗技术的未来发展和对 GBM 特异性免疫反应的深入了解可能会导致更有针对性和更有效的治疗方法。尽管有希望，但进一步的研究对于验证和优化 mRNA 疫苗在对抗 GBM 方面的有效性至关重要。
